Health Condition 1: H357- Separation of retinal layers
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
N K P Salve Institute of Medical Sciences and Research Centre , Nagpur
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients above 18 years of age, compliant for follow-up and willing to participate 2. Patients of type I and type II Diabetes mellitus presenting with diabetic macular oedema resulting in visual loss 3. Study eye having best corrected visual acuity of less than 6/12. Macular oedema defined clinically and by SD- OCT as retinal thickness of more than 250µm in the central sub-field and presence of intra or sub-retinal fluid . 4. Treatment with intravitreal bevacizumab (atleast one injection) in past 6 months.
Exclusion criteria
Exclusion criteria: 1. Other retinal diseases which can cause macular oedema like retinal vascular disorders, choroidal neovascular membrane secondary to age related macular degeneration or any other cause, uveitis 2. Recent history of any intraocular surgery leading to macular oedema 3. Any other cause of loss of visual acuity except cataract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •The correlation between DRIL and functional (BCVA) and anatomical (CST) outcomes over 6 months.Timepoint: •The correlation between DRIL and functional (BCVA) and anatomical (CST) outcomes over 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| • The change in DRIL after treatment with intra vitreal bevacizumab and the correlation between patients’ clinical and OCT measures and DRIL during the study period.Timepoint: 6 MONTHS | — |
Countries
India
Contacts
Public ContactDr Deepa Ajitkumar
N KP Salve Institute of Medical Sciences and Research Centre and Lata Mangeshkar Hospital
Outcome results
None listed